Ro is what the GLP-1 telehealth category looks like when it grows up: operating since 2017, brand-name medication only, real clinical infrastructure, and pricing that reflects all three. The question its review has to answer is not legitimacy: it is whether the premium over budget compounded platforms buys anything you need.
Quick facts (published data, August 2026)
| Medications | Brand-name only: Wegovy (pill and pen), Zepbound, Ozempic off-label; no compounded GLP-1s |
| Published pricing | $39 first month, then $149/mo membership; medication from $149 (Wegovy pill) to $299+ (Zepbound), self-pay |
| All-in monthly | Roughly $348 to $648 depending on drug and dose |
| Insurance | Not billed directly; concierge team handles prior authorizations, which can cut costs sharply if covered |
| Reputation snapshot | Trustpilot 3.8 across ~4,500 reviews; BBB grade B; App Store 4.8 (~9,500 ratings) |
| Track record | Operating since 2017, one of the oldest telehealth brands in the US |
What works
- Brand-name-only strategy removes the entire compounded-medication legal gray zone from the equation.
- The insurance concierge is genuinely valuable: prior authorization is the difference between $650 and a copay for covered patients.
- Mature operation: nearly a decade of telehealth, mainstream app quality, real clinical protocols.
- Transparent product pages with visible pricing tiers, rare in this market.
What to watch
- All-in cost at self-pay ($348 to $648/mo) is two to four times the budget compounded platforms; the premium buys authenticity and process, not stronger medicine.
- Trustpilot 3.8 is middling for the category; themes cluster on support responsiveness at scale rather than product issues.
- Membership continues billing whether or not medication issues resolve quickly; factor the subscription into any pause.
- Ozempic off-label prescribing is standard practice but means the diabetes brand at weight-loss intent; insurance implications differ.
Who it fits, who it doesn't
A reasonable fit for: Buyers who want brand pens and zero compounding ambiguity, people with likely insurance coverage (the concierge earns its fee), and anyone prioritizing an established operator over price.
Look elsewhere if: Price-first buyers (the compounded tier exists for a reason), and anyone expecting insurance billing handled end to end: Ro coordinates, you still pay or claim.
What the reviews say
Aggregated themes from public review platforms, with attribution. We summarize patterns rather than quoting individuals; ratings and themes reflect the public record as of August 2026.
Trustpilot: 3.8 across ~4,500 reviews
- Positive threads: smooth onboarding, legitimate prescriptions, the concierge actually obtaining prior authorizations.
- Negative threads: support lag during demand spikes, membership billing during medication delays.
BBB: grade B
- Complaint volume consistent with a large operator; billing and cancellation themes dominate, resolution rate reasonable.
App Store: 4.8 across ~9,500 ratings
- The strongest public signal Ro has: product experience rates far above the category norm.
How this review was made
Desk review from Ro's published pricing pages, Trustpilot and BBB records, and app-store data as of August 2026. No hands-on test order yet; the page will be upgraded when we complete one.
Compounded GLP-1s sit in a narrow legal lane since the shortages ended; before choosing any provider on this model, read the legality guide and the GLP-1 name decoder.
Frequently asked questions
Is Ro legit?
Among the most established operators in US telehealth: since 2017, licensed prescribers, brand-name-only GLP-1s. The legitimacy question Ro actually raises is economic: whether its premium fits your insurance situation.
How much does Ro Body cost per month?
Membership runs $149/month after a $39 first month, plus medication from $149 (Wegovy oral) to $299 and up (Zepbound tiers): roughly $348 to $648 all-in at self-pay, before any insurance coverage the concierge secures.
Does Ro use compounded semaglutide?
No. Ro's program is brand-name only (Wegovy, Zepbound, off-label Ozempic), which sidesteps the entire post-shortage compounding controversy at a price that reflects it.